Thank you, Mr. Chair.
Ms. Langlois and Ms. Lelièvre, in a December 6, 2021, article, Mr. Fabien Paquette of Pfizer Canada says that, according to the industry, lifting the patents “...is more likely to generate undue pressure on demand and already tight raw material management, limit production capacity for highly efficient sites, and discourage the innovation that has served us so well in the development of vaccines in record time.”
What do you think of this kind of argument?